Corline Biomedical AB (FRA:IZ7) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IZ7 Corline Biomedical AB FRA:IZ7
43 GF Score
Price €1.45
GF Value €0.79
! 4 Warning Signs
View Full Analysis

What is Corline Biomedical AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Corline Biomedical AB Quality Rank Related Terms

FRA:IZ7
43GF Score
Corline Biomedical AB FRA:IZ7
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?

Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued. The current stock price of €1.45 is trading 82.9% above its estimated GF Value™ of €0.79.

Key valuation signals for FRA:IZ7:

  • Quality Rank:
  • GF Value™: €0.79 vs. price of €1.45 (82.9% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corline Biomedical AB Business Description

Other Exchanges CLBIO:Sweden
Address Lefflersgatan 5, Uppsala, SWE, 754 50
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score

Get the complete analysis for FRA:IZ7

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€0.79
GF Value